Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase 3 2Phase 1/2 2Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell, Marginal Zone 1Lymphatic Diseases 1Leukemia, B-Cell 1Heart Failure 1

Interventions

Rituximab 2orelabrutinib 1obinutuzumab 1Thiotepa 1Radiotherapy 1Filgrastim 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, B-Cell, Marginal Zone × obinutuzumab × Clear all
NCT07355699 2026-01-21

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Beijing Tongren Hospital

Phase 4 Recruiting
88 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡